bendamustine hydrochloride has been researched along with Abnormalities, Autosome in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Castro-Prado, MAA; Franco, CCDS; Mathias, PCF; Morais, JF; Pereira, TS; Sant'anna, JR; Yajima, JPRS | 1 |
| Brychtova, Y; Brzobohata, A; Doubek, M; Mayer, J; Mraz, M; Panovska, A; Pavlova, S; Pospisilova, S; Skuhrova Francova, H; Spunarova, M; Tom, N; Trbusek, M | 1 |
| Di Bona, E; Finotto, S; Laveder, F; Paolini, R; Pomponi, F; Rodeghiero, F; Ruggeri, M; Sartori, R; Trentin, L; Visco, C | 1 |
| Bahlo, J; Bergmann, M; Binder, M; Böttcher, S; Cramer, P; Döhner, H; Dreyling, M; Eichhorst, B; Fink, AM; Fischer, K; Fischer, N; Gross-Ophoff, C; Hallek, M; Kluth, S; Kneba, M; Kreuzer, KA; Langerbeins, P; Maurer, C; Pflug, N; Rhein, C; Stilgenbauer, S; Tausch, E; Wendtner, CM | 1 |
1 trial(s) available for bendamustine hydrochloride and Abnormalities, Autosome
| Article | Year |
|---|---|
Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chromosome Aberrations; Drug Administration Schedule; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Rituximab; Thalidomide; Treatment Outcome | 2016 |
3 other study(ies) available for bendamustine hydrochloride and Abnormalities, Autosome
| Article | Year |
|---|---|
Assessment of bendamustine-induced genotoxicity in eukaryotic cells.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Aspergillus nidulans; Bendamustine Hydrochloride; Cells, Cultured; Chromosome Aberrations; Dose-Response Relationship, Drug; Humans; Loss of Heterozygosity; Lymphocytes; Micronuclei, Chromosome-Defective; Micronucleus Tests; Young Adult | 2019 |
Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Tumor; Chromosome Aberrations; Chromosomes, Human, Pair 11; Cohort Studies; Cyclophosphamide; Female; Follow-Up Studies; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Prognosis; Rituximab; Survival Rate; Vidarabine | 2019 |
The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chromosome Aberrations; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; Cytarabine; Cytogenetic Analysis; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Nitrogen Mustard Compounds; Pilot Projects; Recurrence; Risk; Rituximab; Sequence Deletion; Survival Analysis | 2013 |